

24-Month Clinical results for Healionics' STARgraft featured at CiDA conference

SEATTLE, WA, UNITED STATES, November 4, 2025 /EINPresswire.com/ -- Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced the presentation of 24-month clinical results for its STARgraft arteriovenous (AV) graft at last week's [Controversies in Dialysis Access](#) (CiDA) Symposium, the leading educational forum for surgeons, radiologists, nephrologists and medical staff who care for dialysis patients. The presentation by Dr. John Ross, a leading expert in vascular access for dialysis, is available at www.healionics.com/publications.



STARgraft vascular graft

STARgraft is intended to provide kidney failure patients with a safer and more reliable means to access the bloodstream for dialysis treatment. It is designed to resist the two most common causes of failure in on-market AV grafts: occlusion (flow blockage) and infection.

In its latest clinical trial, STARgraft showed remarkable promise in addressing both issues and reducing the need for interventions to maintain graft function. STARgraft maintained 100% Primary Unassisted Patency (PUP) through 12 months post-implant (meaning zero interventions were required to maintain sufficient blood flow for dialysis therapy) and 80% PUP through 24 months. STARgraft also maintained a 0% infection rate through 24 months.

These results contrast sharply with the poor outcomes of on-market AV grafts, which have a PUP of just 41% at 12 months and 28% at 24 months, and infection rates of 9% per year ([Halbert et al., 2020](#)).

Clinical evidence of STARgraft's mechanism of action was also presented at CiDA.

"On-market grafts fail at high rates after they stiffen with time due to constriction effects from scar tissue encapsulation," commented Healionics founding CTO Andrew Marshall. "STARgraft is the first vascular graft demonstrated to maintain long-term flexibility in the graft wall and connected outflow vein, and we are pleased to present clinical evidence supporting this novel

mechanism of action.”

About Dialysis and Vascular Grafts

More than 550,000 people in the United States suffer from kidney failure and require frequent dialysis to filter waste from their blood. Current methods of creating and maintaining regular bloodstream access for dialysis are risky, unreliable and costly, driving a significant portion of the \$50 billion the U.S. spends each year to treat kidney failure. An arteriovenous vascular graft (synthetic blood vessel) is often implanted to create an access site with sufficient flow rate for dialysis, but existing grafts frequently fail due to occlusion and/or infection. Healionics’ innovative STARgraft vascular graft, based on proprietary synthetic biomaterial technology, is designed to resist both problems.

STARgraft is an investigational device not yet available for commercial sale.

About Healionics Corp.

Healionics is a privately held medical device company in Seattle that aims to improve the health, longevity, and quality of life of kidney failure patients while reducing treatment cost.

www.healionics.com

Mike Connolly

Healionics Corp.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/864015232>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.